Form 4: ANI Pharmaceuticals Executive Chad Gassert Sells 20,000 Shares

Chad Gassert, SVP of Corporate Development & Strategy at ANI Pharmaceuticals, sold 20,000 shares of common stock on April 1, 2024, at a weighted average price of $67.25.

Summary

• Chad Gassert, SVP of Corporate Development & Strategy at ANI Pharmaceuticals, sold 20,000 shares of common stock on April 1, 2024.
• The sale was executed at a weighted average price of $67.25 per share, with individual trades ranging from $66.50 to $69.05.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2023.
• Following the transaction, Gassert directly owns 49,679 shares and indirectly owns 253,226 shares through Chali Properties LLC, over which he holds voting and dispositive power.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports a stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Insider selling can be interpreted in various ways by the market, but the existence of a pre-arranged 10b5-1 trading plan suggests the sales were planned in advance and not necessarily based on current company performance.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the pre-arranged nature of the sale mitigates this concern.

Key Dates